PGN-EDODM1
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myotonic Dystrophy 1
Conditions
Myotonic Dystrophy 1
Trial Timeline
Dec 10, 2024 → Aug 1, 2026
NCT ID
NCT06667453About PGN-EDODM1
PGN-EDODM1 is a phase 2 stage product being developed by PepGen for Myotonic Dystrophy 1. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06667453. Target conditions include Myotonic Dystrophy 1.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07220603 | Phase 2 | Recruiting |
| NCT06667453 | Phase 2 | Recruiting |
Competing Products
16 competing products in Myotonic Dystrophy 1
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tideglusib | AMO Pharma | Pre-clinical | 15 |
| Tideglusib | AMO Pharma | Phase 2 | 44 |
| Tideglusib + Placebo | AMO Pharma | Phase 2/3 | 57 |
| Tideglusib | AMO Pharma | Phase 2/3 | 57 |
| VX-670 | Vertex Pharmaceuticals | Phase 2 | 51 |
| VX-670 + Placebo | Vertex Pharmaceuticals | Phase 1/2 | 40 |
| SAR446268 | Sanofi | Phase 1/2 | 40 |
| rhIGF-I/rhIGFBP-3 + placebo | Insmed | Phase 2 | 49 |
| IONIS-DMPKRx + Placebo | Ionis Pharmaceuticals | Phase 1/2 | 38 |
| Del-desiran (AOC 1001) | Avidity Biosciences | Phase 3 | 74 |
| ARO-DM1 Intravenous (IV) Infusion + Placebo Intravenous (IV) Infusion + ARO-DM1 subcutaneous (SC) injection + Placebo Subcutaneous (SC) Injection | Arrowhead Pharmaceuticals | Phase 1/2 | 38 |
| DYNE-101 + Placebo | Dyne Therapeutics | Phase 3 | 72 |
| DYNE-101 + Placebo | Dyne Therapeutics | Phase 1/2 | 36 |
| Pitolisant Oral Tablet + Placebo oral tablet | Harmony Biosciences | Phase 2 | 47 |
| PGN-EDODM1 | PepGen | Phase 2 | 44 |
| PGN-EDODM1 for infusion | PepGen | Phase 1 | 25 |